And then at ESMO, of course, we have the plenary presentation ... our teams have a very established connections with the GU oncology community that hopefully supports the discussion of this ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that three abstracts on BL-B01D1, a ...
Innovations in breast cancer, targeted therapies, antibody-drug conjugates, and kidney cancerNovel treatments, including ...
Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...
These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper Session: GU Tumours, Prostate at 2:45 p.m. CEST. “Despite recent ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
In presentations at European Society for Medical Oncology (ESMO) Congress 2024 ... thoracic medical oncologist at MedStar Georgetown University Hospital and assistant professor at Georgetown ...
Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic ...
ASCO GU, (SGMO)/Meister ConCept GmbH, ESMO, PeerVoice, Pfizer, Silvio Grasso Consulting, EPG Health, and Intellisphere LLC. She has also received travel grants from Bayer, Gilead, and Intellisphere.
ASCO GU, (SGMO)/Meister ConCept GmbH, ESMO, PeerVoice, Pfizer, Silvio Grasso Consulting, EPG Health, and Intellisphere LLC. She has also received travel grants from Bayer, Gilead, and Intellisphere.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback